FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166784182> ?p ?o ?g. }

• W2166784182 abstract "Abstract Background Human adenoviruses (Ads) have substantial potential for clinical applications in cancer patients. Conditionally replicating adenoviruses (CRAds) include oncolytic adenoviruses in which expression of the immediate early viral transactivator protein E1A is controlled by a cancer cell-selective promoter. To enhance efficacy, CRAds are further armed to contain therapeutic genes. Due to size constraints of the capsid geometry, the capacity for packaging transgenes into Ads is, however, limited. To overcome this limitation, the employment of E1A-deleted replication-deficient viruses carrying therapeutic genes in combination with replication-competent CRAd vectors expressing E1A in trans has been proposed. Most trans-complementing studies involved transgene expressions from strong ubiquitous promoters, and thereby relied entirely on the cancer cell specificity of the CRAd vector. Results Here we tested the trans-complementation of a CRAd and a replication-deficient transgene vector containing the same cancer cell-selective promoter. Hereto, we generated two new vectors expressing IL-2 and CD40L from a bicistronic expression cassette under the control of the melanoma/melanocyte-specific tyrosinase enhancer tyrosinase promoter (TETP), which we previously described for the melanoma-specific CRAd vector AdΔEP-TETP. These vectors gave rise to tightly controlled melanoma-specific transgene expression levels, which were only 5 to 40-fold lower than those from vectors controlled by the nonselective CMV promoter. Reporter analyses using Ad-CMV-eGFP in combination with AdΔEP-TETP revealed a high level of trans-complementation in melanoma cells (up to about 30-fold), but not in non-melanoma cells, unlike the AdCMV-eGFP/wtAd5 binary vector system, which was equally efficient in melanoma and non-melanoma cells. Similar findings were obtained when replacing the transgene vector AdCMV-eGFP with AdCMV-IL-2 or AdCMV-CD40L. However, the combination of the novel AdTETP-CD40L/IL-2 vector with AdΔEP-TETP or wtAd5 gave reproducible moderate 3-fold enhancements of IL-2 by trans-complementation only. Conclusions The cancer cell-selective TETP tested here did not give the expected enforceable transgene expression typically achieved in the Ad trans-complementing system. Reasons for this could include virus-mediated down regulation of limiting transcription factors, and/or competition for such factors by different promoters. Whether this finding is unique to the particular promoter system tested here, or also occurs with other promoters warrants further investigations." @default.
• W2166784182 created "2016-06-24" @default.
• W2166784182 creator A5006452839 @default.
• W2166784182 creator A5011549921 @default.
• W2166784182 creator A5028387254 @default.
• W2166784182 creator A5039101695 @default.
• W2166784182 creator A5056886474 @default.
• W2166784182 creator A5089297467 @default.
• W2166784182 date "2010-07-29" @default.
• W2166784182 modified "2023-10-18" @default.
• W2166784182 title "Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro" @default.
• W2166784182 cites W140694299 @default.
• W2166784182 cites W1558969188 @default.
• W2166784182 cites W1969188509 @default.
• W2166784182 cites W1976892064 @default.
• W2166784182 cites W1983224014 @default.
• W2166784182 cites W1988876819 @default.
• W2166784182 cites W2000853857 @default.
• W2166784182 cites W2002453838 @default.
• W2166784182 cites W2003810939 @default.
• W2166784182 cites W2005603741 @default.
• W2166784182 cites W2006202262 @default.
• W2166784182 cites W2006929107 @default.
• W2166784182 cites W2010315788 @default.
• W2166784182 cites W2010502399 @default.
• W2166784182 cites W2010869741 @default.
• W2166784182 cites W2011942975 @default.
• W2166784182 cites W2016533804 @default.
• W2166784182 cites W2019236193 @default.
• W2166784182 cites W2020692896 @default.
• W2166784182 cites W2020920166 @default.
• W2166784182 cites W2023815703 @default.
• W2166784182 cites W2027240807 @default.
• W2166784182 cites W2027802510 @default.
• W2166784182 cites W2030651520 @default.
• W2166784182 cites W2039618053 @default.
• W2166784182 cites W2041649745 @default.
• W2166784182 cites W2053474695 @default.
• W2166784182 cites W2065522069 @default.
• W2166784182 cites W2068644182 @default.
• W2166784182 cites W2073949850 @default.
• W2166784182 cites W2074163433 @default.
• W2166784182 cites W2076429505 @default.
• W2166784182 cites W2089183795 @default.
• W2166784182 cites W2090864647 @default.
• W2166784182 cites W2098264302 @default.
• W2166784182 cites W2104500895 @default.
• W2166784182 cites W2113127264 @default.
• W2166784182 cites W2114216165 @default.
• W2166784182 cites W2114941806 @default.
• W2166784182 cites W2118511790 @default.
• W2166784182 cites W2121854846 @default.
• W2166784182 cites W2125980219 @default.
• W2166784182 cites W2134666108 @default.
• W2166784182 cites W2145630676 @default.
• W2166784182 cites W2148377255 @default.
• W2166784182 cites W2154352878 @default.
• W2166784182 cites W2158744232 @default.
• W2166784182 cites W2159813540 @default.
• W2166784182 cites W2160107647 @default.
• W2166784182 cites W2165842882 @default.
• W2166784182 cites W2323062703 @default.
• W2166784182 cites W34464345 @default.
• W2166784182 cites W4244980457 @default.
• W2166784182 cites W4250635458 @default.
• W2166784182 doi "https://doi.org/10.1186/1743-422x-7-175" @default.
• W2166784182 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2920257" @default.
• W2166784182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20670430" @default.
• W2166784182 hasPublicationYear "2010" @default.
• W2166784182 type Work @default.
• W2166784182 sameAs 2166784182 @default.
• W2166784182 citedByCount "6" @default.
• W2166784182 countsByYear W21667841822013 @default.
• W2166784182 countsByYear W21667841822015 @default.
• W2166784182 countsByYear W21667841822016 @default.
• W2166784182 countsByYear W21667841822017 @default.
• W2166784182 countsByYear W21667841822018 @default.
• W2166784182 crossrefType "journal-article" @default.
• W2166784182 hasAuthorship W2166784182A5006452839 @default.
• W2166784182 hasAuthorship W2166784182A5011549921 @default.
• W2166784182 hasAuthorship W2166784182A5028387254 @default.
• W2166784182 hasAuthorship W2166784182A5039101695 @default.
• W2166784182 hasAuthorship W2166784182A5056886474 @default.
• W2166784182 hasAuthorship W2166784182A5089297467 @default.
• W2166784182 hasBestOaLocation W21667841821 @default.
• W2166784182 hasConcept C100012643 @default.
• W2166784182 hasConcept C102230213 @default.
• W2166784182 hasConcept C104317684 @default.
• W2166784182 hasConcept C111599444 @default.
• W2166784182 hasConcept C111936080 @default.
• W2166784182 hasConcept C127716648 @default.
• W2166784182 hasConcept C1292079 @default.
• W2166784182 hasConcept C140704245 @default.
• W2166784182 hasConcept C150194340 @default.
• W2166784182 hasConcept C153911025 @default.
• W2166784182 hasConcept C159047783 @default.
• W2166784182 hasConcept C161733203 @default.
• W2166784182 hasConcept C188082640 @default.
• W2166784182 hasConcept C2522874641 @default.
• W2166784182 hasConcept C2776954459 @default.

• next